Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)
NCT06711770 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-07-30
Summary
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms. CSC are able to circulate within blood, protected from destruction by immunosuppressive cells such as MDSC. Some factors such as G-CSF, administered to lower febrile neutropenia, should modulate properties of MDSC and CSC, but data are contradictory, and literature remain poor regarding its effects on the interactions between MDSC and CSC in blood clusters. Indeed, this project aims at better characterizing the effect of G-CSF on these interactions and on their functions in NSCLC patients receiving G-CSF.
Conditions
- Non Small Cell Lung Cancer
- Immunotherapy
- Granulocyte Colony Stimulating Factor
Interventions
- BIOLOGICAL
-
Blood sample
Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-31
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- France
Study Locations
More Related Trials
-
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
NCT03638765 ·Status: UNKNOWN ·Phase: PHASE1
-
Tumor-specific T Cells in Lung Cancer
NCT02515760 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
NCT02978118 ·Status: ACTIVE_NOT_RECRUITING
-
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653 ·Status: TERMINATED ·Phase: PHASE3
-
Lymphocytes Subpopulation in Cancer Patients
NCT02516371 ·Status: UNKNOWN ·Phase: NA
-
Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases
NCT06877364 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
NCT05040568 ·Status: COMPLETED ·Phase: PHASE1
-
Deciphering Mechanisms Underlying Cancer Immunogenicity
NCT03958240 ·Status: RECRUITING ·Phase: NA
-
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269 ·Status: RECRUITING ·Phase: NA
-
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01171469 ·Status: COMPLETED ·Phase: PHASE1
-
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
NCT03134027 ·Status: TERMINATED
-
CD30 CAR for CD30+ NSGCT
NCT05634785 ·Status: COMPLETED ·Phase: PHASE2
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)
NCT04615845 ·Status: TERMINATED ·Phase: PHASE1
-
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
NCT02692976 ·Status: COMPLETED ·Phase: PHASE2
-
GI Complications in Cancer Immunotherapy Patients
NCT02784366 ·Status: UNKNOWN
-
Safety Study of Adoptive Transfer of Autologous IKDC-like Cells
NCT02661685 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Blood Immune Cells in Cancer Patients Compared to Controls
NCT01312701 ·Status: UNKNOWN
-
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
NCT00923390 ·Status: TERMINATED ·Phase: PHASE1
-
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT05035407 ·Status: TERMINATED ·Phase: PHASE1